Evidence map›Paper›PMID 41545844›Full record

ReviewBiomarker research2026

Migrasome and cancer - from cellular to clinical perspectives.

Zijie Guo, Yihong Wen, Qina He, Ziyu Zhu, Xixi Lin, Maryam Maleki Goli, Parnia Ghanad, Feiyang Ji, Linbo Wang, Lili Zhi and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biomarker research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Zijie Guo *Department of Surgical Oncology, Affiliated Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, No.3 East Qingchun Road, Hangzhou, Zhejiang, 310016, China.
Yihong Wen *Biomedical Research Center and Key Laboratory of Biotherapy of Zhejiang Province, Hangzhou, Zhejiang, 310016, China.
Qina He *Department of Surgical Oncology, Affiliated Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, No.3 East Qingchun Road, Hangzhou, Zhejiang, 310016, China.
Ziyu ZhuDepartment of Surgical Oncology, Affiliated Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, No.3 East Qingchun Road, Hangzhou, Zhejiang, 310016, China.
Xixi LinDepartment of Surgical Oncology, Affiliated Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, No.3 East Qingchun Road, Hangzhou, Zhejiang, 310016, China.
Maryam Maleki GoliDepartment of Surgical Oncology, Affiliated Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, No.3 East Qingchun Road, Hangzhou, Zhejiang, 310016, China.
Parnia GhanadDepartment of Surgical Oncology, Affiliated Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, No.3 East Qingchun Road, Hangzhou, Zhejiang, 310016, China.
Feiyang JiDepartment of Surgical Oncology, Affiliated Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, No.3 East Qingchun Road, Hangzhou, Zhejiang, 310016, China. feiyangji@zju.edu.cn.
Linbo WangDepartment of Surgical Oncology, Affiliated Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, No.3 East Qingchun Road, Hangzhou, Zhejiang, 310016, China. linbowang@zju.edu.cn.
Lili ZhiBiomedical Research Center and Key Laboratory of Biotherapy of Zhejiang Province, Hangzhou, Zhejiang, 310016, China. 3324137@zju.edu.cn.
Jichun ZhouDepartment of Surgical Oncology, Affiliated Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, No.3 East Qingchun Road, Hangzhou, Zhejiang, 310016, China. jichun-zhou@zju.edu.cn.

Funding

National Natural Science Foundation of China, China No. 82272855, No. 81972453, No. 81972597Natural Science Foundation of Zhejiang Province Grant Nos. LR22H160011, LY19H160055, LY19H160059, LY18H160005, and LY20H160026Zhejiang Provincial Medical and Health Science and Technology (Youth Talent Program) Project No. 2021RC016
6 · The paper itself

Abstract

Migrasomes, a newly discovered class of extracellular organelles, have emerged as pivotal mediators of intercellular communication, signaling gradient establishment, and organelle homeostasis. Their unique biogenesis—arising from retraction fibers of migrating cells—positions them as critical regulators in both physiological and pathological processes, particularly in cancer. Recent studies have revealed that migrasomes play multifaceted roles in cancer initiation, progression, metastasis, and drug resistance by orchestrating cell-cell communication, modulating the tumor microenvironment (TME), and facilitating the transfer of oncogenic biomolecules. This review systematically summarizes current knowledge on migrasome biogenesis and functions, critically analyzes their multifaceted involvement in cancer biology, and evaluates their potential as diagnostic biomarkers and therapeutic targets. Importantly, we highlight recent advances in migrasome-based cancer research and discuss future directions for translating these findings into clinical applications.

Indexed as

CancerCancer biologyCell migrationClinical applicationMigrasomeTumor microenvironment

Identifiers

PMID41545844
PMCPMC12829089

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.